Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 5/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MC2R | Q01718 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296635 | 0.94 | ACP1 (0.34) | ACP1CHRM3CNR1CNR2HCRTR1 | |
| SCHEMBL13705440 | 0.92 | ACP1 (0.34) | ACP1CHRM3HCRTR1HCRTR2 | |
| SCHEMBL13705453 | 0.89 | HCRTR2 (0.34) | CHRM3CNR1CNR2HCRTR1HCRTR2 | |
| SCHEMBL13705403 | 0.88 | CHRM3 (0.34) | ACP1CHRM3HCRTR1HCRTR2 | |
| SCHEMBL13705448 | 0.86 | HCRTR1 (0.41) | CHRM3HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL4283035 | 0.86 | ACP1 (0.35) | ACP1CHRM3HCRTR1HCRTR2 | |
| SCHEMBL13705437 | 0.86 | ACP1 (0.33) | ACP1HCRTR1HCRTR2 | |
| SCHEMBL13705444 | 0.86 | HCRTR2 (0.40) | CHRM3CNR1CNR2HCRTR1HCRTR2 | |
| SCHEMBL4753383 | 0.85 | CHRM3 (0.32) | ACP1CHRM3HCRTR1HCRTR2 | |
| SCHEMBL13810259 | 0.84 | ACP1 (0.34) | ACP1CHRM3HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | ACP1 3629/4885CHRM3 3197/4885CNR1 3488/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | ACP1 3629/4885CHRM3 3197/4885CNR1 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.